Cannabis Industry Overview Now That Trump is President Again

The cannabis industry has been on a rapid, sometimes rocky journey in the U.S. over the past decade. With 39 states having some form of legalized cannabis, the industry has flourished, attracting investors, entrepreneurs, and millions of customers. Now, Donald J. Trump is officially back in office after the 2024 election. With Trump’s win, what will the future hold for cannabis? If you’re reading this, you surely are wondering what Trump’s cannabis policies might be. There are both hopes and concerns among industry insiders and advocates.

Let’s break down how Trump’s return to the presidency might impact cannabis in the years to come, covering the possible effects on legalization, regulation, investments, social equity, research, and what it all means for the everyday cannabis enthusiast.

A Look Back: Trump’s Cannabis Policies Previously

Understanding what Trump might do in his second term starts with looking at his first term’s approach to cannabis. Trump mostly stayed quiet on cannabis legalization, supporting states’ rights to set their own cannabis policies rather than pursuing any significant federal action. Though he did sign the 2018 Farm Bill, which legalized hemp and CBD products, cannabis still remained federally prohibited.

With his return to office, Trump’s past stance suggests he may continue a “hands-off” approach, leaving the issue to states and focusing on decriminalization rather than full legalization. This mixed stance creates an uncertain future for cannabis entrepreneurs, investors, and consumers alike.

The Federal vs. State Legalization Divide

The cannabis industry has been flourishing under a patchwork of state laws, with some states fully legalizing recreational and medical cannabis while others hold out. Under Trump, this state-driven model is likely to continue. His conservative stance suggests he won’t likely push for sweeping federal legalization, but he may support limited measures like decriminalization.

This means cannabis could remain a Schedule I substance, with strict limitations at the federal level. While states might continue to legalize recreational and medical cannabis independently, a lack of federal action creates complications for cannabis companies trying to grow beyond state borders.

Key Points to Consider:

• Decriminalization over Legalization: Trump might favor a middle ground, reducing criminal penalties while keeping cannabis federally illegal.
• Ongoing Federal Restrictions: Without federal legalization, cannabis companies will still face limitations on banking, transportation across state lines, and investment opportunities.

Decriminalization vs. Legalization: Where Trump’s Cannabis Policies Stand

There’s a big difference between decriminalization (removing or reducing penalties for possession) and full legalization (creating a federally regulated market). Trump’s likely approach in 2024 would lean toward decriminalization, aligning with conservative principles while offering a middle-ground solution to address public demand for reform.

If the Trump administration focuses on decriminalization, it would likely reduce or eliminate federal penalties for cannabis possession, which could be beneficial for individuals in states without legal cannabis access. However, decriminalization won’t create the same business-friendly environment as legalization, as cannabis businesses would still be unable to access key resources like banking and interstate commerce.

Potential Impact of Decriminalization:

• Reduced Criminal Penalties: Possession and use may carry lighter federal penalties, easing concerns for users.
• Restricted Growth for Businesses: Companies will continue to face hurdles in banking, insurance, and federal funding, hindering national expansion.

Impact on Cannabis Stocks and Investment Trends

The stock market has been closely tied to the federal outlook on cannabis. The cannabis sector saw dramatic highs and lows over the past decade, and Trump’s cannabis policies could affect stocks once again.

With decriminalization instead of full legalization, cannabis stocks might see a temporary boost as businesses hope for regulatory relief. However, without comprehensive federal reform, investors may remain wary of long-term investments in cannabis. Large institutional investors and hedge funds could continue holding off, waiting for the federal status to change before diving into the cannabis market fully.

Investment Insights for the Industry:

• CBD and Wellness Stocks: Given Trump’s 2018 approval of CBD legalization, companies in the CBD and wellness markets may fare better than those in recreational cannabis.
• Cautious Investment Climate: Without federal protections, the cannabis industry may struggle to attract large-scale investments and major institutional investors.

Federal Regulation and the Rise of Big Business

While small businesses and local dispensaries have defined much of the U.S. cannabis scene, a second Trump administration could see increased interest from big corporations looking to enter the market. Trump’s pro-business approach might create regulatory frameworks that encourage larger corporations, including those from tobacco and pharmaceutical sectors, to enter cannabis with more standardized products.

If big corporations enter the cannabis industry in a regulated, decriminalized environment, this could mean changes for product availability and quality, and increased competition for smaller dispensaries and brands.

How Big Business Might Influence Cannabis:

• Standardized, Mass-Market Products: With big businesses joining, products may become more standardized, shifting away from the craft cannabis feel.
• Increased Competition for Small Businesses: Local dispensaries and smaller brands may face challenges keeping up with larger corporate competition and regulatory costs.

Social Equity in Cannabis: Concerns and Opportunities

One of the most important issues facing cannabis legalization has been social equity—making sure communities affected by the War on Drugs have opportunities within the industry. Trump’s cannabis policies previously supported some criminal justice reform, such as the First Step Act, which was aimed at prison reform and giving offenders a second chance. This opens the door for potential support for social equity initiatives, though it may not be a high priority.

If Trump’s administration focuses on business over social reform, the industry could miss an opportunity to prioritize marginalized communities. Advocates may need to push harder to ensure social equity remains a part of any federal cannabis reform.

Social Equity Considerations:

• Minimal Federal Support: Social equity provisions may not be a primary focus under Trump, meaning state-level action could be essential.
• Risk of Corporate Dominance: Larger businesses may overshadow smaller, equity-focused enterprises without specific federal protections.

Cannabis Research and Medical Advancements

Federal restrictions have hampered cannabis research in the U.S., making it difficult to fully understand the plant’s medicinal potential. If Trump leans toward decriminalization without full legalization, the door could still open for research expansion.

By reducing restrictions on research, a Trump administration could allow more scientific studies on cannabis’s potential benefits for conditions like chronic pain, anxiety, and epilepsy. However, conservative-leaning research priorities might limit studies focused on recreational use, focusing more on medical applications.

Research Outlook:

• Increased Access for Medical Studies: Federal decriminalization could open the door for more clinical research and FDA-approved studies.
• Focus on Medical, Not Recreational: Research might focus on medical benefits rather than recreational use, appealing to more conservative voter bases.

What This Means for Cannabis Enthusiasts

For the everyday cannabis enthusiast, Trump’s cannabis policies in his second term could have a mixed bag of effects. Here’s what to expect:

• Cannabis-Friendly States Remain: In states where cannabis is already legal, access to dispensaries and products won’t change much.
• Federal Gray Zone: Without federal legalization, cannabis will remain a legal risk when crossing state borders, and banking restrictions will persist.
• New Faces in the Industry: Expect larger corporate brands to potentially enter the scene, alongside medical products, thanks to potential research expansions.

Conclusion: Preparing for a New Era in Cannabis

With Trump back in office, the cannabis industry faces a future that’s both familiar and filled with questions. While a pro-business Trump administration might support limited reforms, full legalization still feels like a long shot. As federal restrictions remain, state-led momentum and corporate interest will likely drive the market forward.

For now, the best advice for cannabis entrepreneurs, investors, and consumers is to stay informed and flexible. Whether the focus is on decriminalization, medical research, or corporate investment, 2024 marks the beginning of a new chapter in the complex journey of cannabis in America.

Join us on The HighWay.